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Objective: We sought to investigate the durability and mechanism of the Carpentier-
Edwards pericardial xenograft in the mitral position in comparison with that of the
Ionescu-Shiley pericardial xenograft.
Methods: A total of 284 patients who received the Ionescu-Shiley pericardial xenograft
in the mitral position between 1980 and 1984 and 84 patients who received the
Carpentier-Edwards pericardial xenograft in the mitral position between 1984 and
1999 were included in the study. The freedom from reoperation rates for both graft
types were determined. For morphologic study, the pathologic findings of 23 valves of
123 explanted Ionescu-Shiley pericardial xenografts with structural valve deterioration,
nonstructural valve deterioration, or both were determined and compared with those of
20 explanted Carpentier-Edwards pericardial xenografts with structural valve deterio-
ration, nonstructural valve deterioration, or both. Each pathologic finding was graded
and assigned a score. Both types were matched for age at reoperation (50-75 years) and
duration of valve function (8-11 years).
Results: Freedom from reoperation caused by structural valve deterioration, non-
structural valve deterioration, or both was significantly better for Carpentier-
Edwards pericardial xenografts than for Ionescu-Shiley pericardial xenografts at 8
years after the operation (Carpentier-Edwards pericardial xenografts: 91.3% vs
Ionescu-Shiley pericardial xenografts: 71.9%, P = .0061), but it was similar for both
types at 12 years (Carpentier-Edwards pericardial xenografts: 43.6% vs Ionescu-
Shiley pericardial xenografts: 43.6%, P = .2865). No severe leaflet tears were seen
among Carpentier-Edwards pericardial xenografts. The mean area percentage of tis-
sue overgrowth was 15.3% in Carpentier-Edwards pericardial xenografts and 3.4%
in Ionescu-Shiley pericardial xenografts (P = .0001). The mean calcification area
percentage was 13.6% in Carpentier-Edwards pericardial xenografts and 31.5% in
Ionescu-Shiley pericardial xenografts (P = .0001).
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The first generation of pericardial valves, theIonescu-Shiley pericardial xenograft (ISPX;Shiley Laboratories, Irvine, Calif), was thefirst choice among bioprostheses for valvereplacement at the National CardiovascularCenter, Osaka, Japan, between 1980 and
1984. However, it has been withdrawn from clinical use
because of the observed high rate of valve insufficiency
characterized by calcification and leaflet tears.1-4 The
Carpentier-Edwards pericardial xenograft (CEPX; Baxter
Healthcare Corp, Santa Ana, Calif), the second generation
of pericardial valves, which was designed to provide a supe-
rior hemodynamic performance and better durability than
its predecessors, has been used in our institute since 1984.
The intermediate follow-up period of CEPXs has shown low
rates of valve-related events, especially valve deterioration
after leaflet tears.5,6 However, its durability in the mitral
position has been of considerable concern for cardiologists.
According to the results of operations performed at our
institute, it was reported that up to 4 years after valve
replacement, the incidence of bioprosthetic valve failure
was lower for CEPXs compared with for ISPXs.7,8
Recently, however, after more than 10 years of experience
with CEPXs, the number of patients undergoing a second
valve replacement because of prosthetic valve failure has
been increasing in our institute.
The purpose of this study was to investigate the durabil-
ity and the mechanism of primary failure of CEPXs at a sin-
gle institute, with emphasis on the pathologic findings of
explanted valves in comparison with ISPXs.
Patients and Methods
At our institute, between 1980 and 1984, 284 patients received
ISPX valves in the mitral position (ISPX group), and since 1984,
84 patients received CEPX valves (CEPX group) in the mitral
position. The patient population of the ISPX group consisted of
117 (41.2%) men and 167 (58.8%) women, with an age range of
18 to 73 years (mean, 50.0 years); the CEPX group consisted of 32
(38.1%) men and 52 (61.9%) women, with an age range of 18 to
80 years (mean, 57.5 years) (Table 1). In the CEPX group 73.1%
and 24.3% of patients were shown to have chronic atrial fibrillation
and sinus rhythm, respectively. In the ISPX group 81.6% and
18.0% of patients were shown to have chronic atrial fibrillation and
sinus rhythm, respectively.
Patients were operated on through a median sternotomy with
standard cardiopulmonary bypass, hemodilution, and moderate
hypothermia. Myocardial protection was obtained with crystalloid
or blood cardioplegia and topical cooling. Bioprosthetic valves
were implanted in the para-annular position by using an everting
mattress suture technique with pledgets.
Postoperative warfarin anticoagulation was initiated as soon as
oral administration became possible and was continued for as long
as 3 months. Patients with atrial fibrillation, however, were main-
tained on warfarin therapy for longer durations; the treatment was
sometimes modified according to the cardiologist’s decision.
Finally, 53.4% and 68.4% of the patients with atrial fibrillation
were maintained on warfarin therapy for longer durations in the
CEPX group and the ISPX group, respectively. An adequate anti-
coagulation state was that in which the prothrombin time ranged
from 25% to 45%, which was equivalent to 2.9 to 1.8 times the
control prothrombin time international normalized ratio.
At present, 123 patients with ISPXs and 25 patients with CEPXs
underwent a second mitral valve replacement because of structural
valve deterioration (SVD), nonstructural valve dysfunction (NSVD),
or both. The average functioning duration of prostheses was 9.3 ±
1.7 years (range, 7.5-12.2 years) in the CEPX group and 7.9 ± 3.2
years (range, 0.5-18.2 years) in the ISPX group. The mean age of
patients at reoperation was 61.0 ± 10.5 years (range, 30-77 years) in
the CEPX group and 57.1 ± 9.6 years (range, 26-78 years) in the
ISPX group. Twenty-three ISPXs with a functioning duration of 8.0
to 11.0 years in patients between 41 and 65 years of age were select-
ed (mean age at explantation, 62.8 years; average functioning dura-
tion, 9.4 years) to match the average functioning duration of pros-
theses and patient age of both groups. ISPX valves that were not
available for re-examination and 4 CEPX valves from patients with
infective endocarditis were excluded from the morphologic and
histopathologic evaluation. Eventually, 23 valves of 123 explanted
ISPXs and 20 valves of 25 explanted CEPXs were examined for
macroscopic and microscopic study. This selection was done before
histologic analysis was started. The size of each explanted valve was
larger than 25 mm in diameter.
Clinical and operative data were obtained from medical records
of the patients. The “Guidelines for Reporting Morbidity and
Mortality After Cardiac Valvular Operations” were used for defi-
nition of valve-related complications.9 Because most explanted
valves had mingled degenerative change (eg, both moderate calci-
fication and massive pannus formation), the differences between
SVD and NSVD were not very clear, particularly with regard to
pathologic investigation. Therefore in this study we used the terms
SVD and NSVD. Prosthetic valve failure caused by endocarditis or
thrombus formation was excluded from this definition.
The following macroscopic changes of the bioprostheses were
assessed and classified into 4 grades (grades 0-3) as follows: (1)
Conclusions: Tissue overgrowth on the atrial surface, ventricular surface, or both was
the cause of structural valve deterioration, nonstructural valve deterioration, or both of
Carpentier-Edwards pericardial xenografts in adults. This was different from Ionescu-
Shiley pericardial xenograft failure, which resulted from severe calcification and
leaflet tears. Organized thrombi on cusps, in addition to valve design, may have con-
tributed to such tissue overgrowth on Carpentier-Edwards pericardial xenografts.
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the degree of cusp miscoaptation, representing the severity of
opening and closing disturbance; (2) leaflet tears; (3) fibrous tissue
overgrowth from the valve ring (ie, pannus formation on the atrial
surface, the ventricular surface, or both of the valve cusps); and (4)
the degree of thrombus formation. Each pathologic finding was
individually evaluated and graded according to the following crite-
ria: (1) grade 0, no macroscopically detected pathologic changes,
no leaflet tears, and no tissue overgrowth; (2) grade 1 (mild
changes), single and small leaflet tear and small tissue overgrowth;
(3) grade 2 (moderate changes), single but large leaflet tear or mul-
tiple small tears and fibrous tissue overgrowth from the ring reach-
ing the middle of the cusp; and (4) grade 3 (severe changes), more
than 2 large leaflet tears and fibrous tissue overgrowth spread over
most of the cusp.
For histopathologic analysis of the removed bioprostheses, spec-
imens were fixed in 10% buffered formalin, and the cusps were cut
from the suture ring to the tip at midcusp region. Then thin 3- to 4-
µm paraffin sections were stained with hematoxylin and eosin,
Masson’s trichrome, elastic van Gieson, and von Kossa stains.
Stained specimens were measured by using a computer morpholog-
ic analyzing system (Nikon Cosmo Zone II, Tokyo, Japan) to deter-
mine the areas of calcification and overgrowing fibrous tissue and
their percentage to the whole surface area of the cusp. These param-
eters were measured in every slice of the cusps for all patients. Also,
the maximal thickness of each cusp was measured by using the ocu-
lar micrometer of the microscope. All histopathologic findings were
evaluated by one experienced pathologist.
Data are reported as means ± SD. The nonparametric freedom
from SVD, NSVD, or both curve was plotted according to the
Kaplan-Meier method. Univariate comparison of SVD-free ratio,
NSVD-free ratio, or both was made with the log-rank test. The
Student t test (for discrete variables) and the χ2 test (for continu-
ous variables) were used for intergroup comparison of pathologic
findings. Multivariate analysis was made with stepwise discrimi-
nant analysis to evaluate the histopathologic changes of explanted
bioprostheses. Parameters for multivariate analysis included
patient age and sex, implanted duration, and pathologic grading of
each valve.
Results
The rate of freedom from reoperation caused by SVD,
NSVD, or both is demonstrated in Figure 1. The freedom
from reoperation rate at 8 years after the operation was sig-
nificantly better in the CEPX group compared with that in
the ISPX group (CEPX group: 91.3% vs ISPX group:
71.9%; P = .0061, log-rank test). However, in the CEPX
group reoperation caused by SVD, NSVD, or both increased
with time, and the 2 actuarial curves crossed at 11 to 12
years after the operation; the rate of freedom from reopera-
tion caused by SVD, NSVD, or both was similar for both
groups at 12 years (CEPX group: 43.6% vs ISPX group:
43.6%; P = .2865, log-rank test). Perivalvular leakage was
evaluated in all patients in the postoperative periods. The
incidence of perivalvular leakage that necessitated a second
mitral valve replacement was 0% (0/84) in the CEPX group
and 1.4% (4/284) in the ISPX group.
The macroscopic findings of the CEPXs (Figure 2, top
left) were as follows: (1) miscoaptation of the cusp closure
lines; (2) tissue overgrowth on the atrial aspect, ventricular
aspect, or both of the valve; and (3) absence of significant
leaflet tears. The macroscopic findings of the ISPXs (Figure
2, bottom left) included the following: (1) nodular intrinsic
calcification of the cusps; (2) leaflet tears starting from the
stent posts; and (3) noticeable rigidity of the cusps.
According to the above-mentioned grading system, grade 2
and 3 leaflet tears were seen in 10 (43.5%) of the 23 patients
with ISPXs. On the other hand, no leaflet tears (grade 0)
were detected in 14 (70.0%) and grade 1 leaflet tears were
seen in only 6 (30.0%) of the 20 patients with CEPXs; grade
2 or 3 leaflet tears were not found in the CEPX group (P =
.002). In about half of the CEPXs, grade 2 or 3 tissue over-
growth was seen on the atrial aspect, the ventricular aspect,
or both. On the other hand, at ISPXs, tissue overgrowth was
less than grade 2 (atrial: P = .0001, ventricular: P = .001).
TABLE 1. Patient characteristics
Carpentier-Edwards pericardial valve Ionescu-Shiley valve
Valve implanted Valve explanted Valve implanted Valve explanted
Variable Total M/F Total M/F Study cases M/F Total M/F Total M/F Study cases M/F
No. of patients 84 32/52 25 6/19 20 5/15 284 117/167 123 42/81 23 5/18
Age at implant (y)
Mean 57.5 51.1 51.3 50.0 49.2 52.6
Range 18-80 23-68 23-68 18-73 18-68 45-63
Duration of implant (y) 9.3 10.1 7.9 9.4
Range (y) 7.5-12.2 7.5-12.2 0.5-18.2 8.0-10.8
Mean age at explant (y) 61.0 61.3 57.1 62.8
Range (y) 30-77 30-77 26-78 54-73
Causes of reoperation
Stenosis 4 4
Regurgitation 6 10
Stenosis and regurgitation 10 9
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The incidence of large thrombi tended to increase among
CEPXs (P = .014) (Table 2).
Histologic examination of ISPXs showed separation of
collagen bundles, cholesterol crystal deposition, and destruc-
tive calcification of the cusps (Figure 2, bottom right).
Examination of CEPXs revealed fibrous tissue overgrowth
on the atrial aspect, the ventricular aspect, or both; serous
insudation of the separated collagen bundles; and band-like
or fine granular intrinsic calcification (Figure 2, top right).
Tissue overgrowth was more frequent in CEPXs, and its area
percentage to the whole cusp area was much wider than that
seen in ISPXs (CEPX: 15.3% ± 12.3% vs ISPX: 3.4% ±
6.5%, P = .0001). Calcification areas were significantly larg-
er among ISPXs compared with among CEPXs (CEPX:
13.6% ± 11.6% vs ISPX: 31.5% ± 10.6%, P = .0001). The
mean cusp thickness of ISPXs was larger than that of CEPXs
(CEPX: 1029.4 ± 4.2 µm vs ISPX: 1509.1 ± 193.1 µm, P =
.012) (Table 3). Cusp thickening might be attributed to
intrinsic calcification and serum insudation. According to the
data from Baxter Co, the cusp thickness of a nonimplanted
new valve ranges from 500 to 600 µm, and therefore both
CEPXs and ISPXs were 2 or 3 times thicker than nonim-
planted valves. The degeneration of cusp collagen bundles
and cholesterol and serum insudation were not significantly
predominant in either type (Table 2).
Multivariate analysis showed that leaflet tears (P = .005),
calcification (P = .035), and tissue overgrowth on the atrial
aspect, the ventricular aspect, or both (P = .013 and P =
.0001, respectively) were significant. Tissue overgrowth on
the ventricular aspect and leaflet tears were the most impor-
tant factors in prognosis of durability of CEPXs and ISPXs,
respectively (Table 4).
Discussion
The present study showed the following: (1) the rate of free-
dom from reoperation caused by SVD, NSVD, or both was
similar at 12 years after the operation in both the CEPX and
ISPX groups; (2) no significant leaflet tears were found
Surgery for Acquired Cardiovascular Disease Machida et al
Figure 1. Actuarial curve of freedom from reoperation caused by SVD, NSVD, or both.
TABLE 2. Pathologic grading of explanted CEPX and ISPX
Carpentier-Edwards valve (n = 20) Ionescu-Shiley valve (n = 23)
0+ 1+ 2+ 3+ 0+ 1+ 2+ 3+ P value
Leaflet tear 14 (70%) 6 (30%) 0 (0%) 0 (0%) 4 (17%) 9 (70%) 9 (39%) 1 (4%) .002*
Tissue overgrowth on atrial aspect 4 (20%) 7 (35%) 6 (30%) 3 (15%) 12 (52%) 11 (48%) 0 (0%) 0 (0%) .0001*
Tissue overgrowth on ventricular aspect 8 (40%) 4 (20%) 5 (25%) 3 (15%) 20 (87%) 3 (13%) 0 (0%) 0 (0%) .001*
Thrombus in atrial aspect 3 (15%) 8 (40%) 4 (20%) 5 (25%) 8 (35%) 13 (57%) 1 (4%) 1 (4%) .014*
Calcification 1 (5%) 9 (45%) 7 (35%) 3 (15%) 2 (9%) 7 (30%) 1 (4%) 13 (57%) .001*
Collagen bundle separation 0 (0%) 3 (15%) 13 (65%) 4 (20%) 0 (0%) 4 (17%) 13 (57%) 6 (26%) .738
Cholesterol deposition 5 (25%) 8 (40%) 7 (35%) 0 (0%) 3 (13%) 11 (48%) 5 (22%) 4 (17%) .312
Serum insudation 0 (0%) 11 (55%) 8 (40%) 1 (5%) 0 (0%) 10 (43%) 11 (48%) 2 (9%) .727
*P < .05.
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among CEPXs; (3) incidence of calcification among CEPXs
was lower compared with that of ISPXs; (4) massive tissue
overgrowth on the atrial aspect, the ventricular aspect, or
both of valves was seen among CEPXs; (5) the incidence of
tissue degeneration of CEPXs (ie, collagen bundle separa-
tion, cholesterol deposition, or serous insudation) was simi-
lar to that of ISPXs; and (6) according to the results of mul-
tivariate analysis, SVD, NSVD, or both of CEPXs caused
by severe tissue overgrowth was the main cause of reopera-
tion after 10 years. Organized thrombi on the cusp surfaces
might have contributed to such tissue overgrowth.
The CEPX valve was designed with an original leaflet
clamping, which eliminated retention suture and risk of
abrasion. The preparatory treatment of the pericardium was
performed with 0.25% to 0.6% buffered glutaraldehyde.
Because of these characteristics, CEPX bioprostheses
showed satisfactory intermediate results in both the aortic
and mitral positions, as reported previously.5,6,10,11
However, our data suggested that despite the durability of
this valve in the mitral position at up to 8 years of follow-
up, the rate of SVD, NSVD, or both beyond this time was
significant. Despite the absence of significant leaflet tears in
Figure 2. Top left, CEPX explanted 11 years after implantation is viewed from the ventricular aspect. Sugar
coat–like tissue overgrowth that induced valve insufficiency is seen. Top right, Microscopic findings of CEPX
cusp showing thick and dense fibrous tissue on the ventricular surface. (Hematoxylin and eosin stain, original
magnification 40×.) Bottom left, ISPX explanted 10 years after implantation is viewed from the ventricular aspect.
Large leaflet tear running toward the cusp-base and granular calcification on the cusp are observed. Bottom right,
Microscopic findings of ISPX cusp demonstrating nodular calcification that destroyed the collagen bundles and
caused increasing thickness of the cusp. (Masson trichrome stain, original magnification 40×.)
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CEPXs, reoperation caused by SVD, NSVD, or both has
increased significantly.
ISPXs, the first generation of pericardial valves, have
been withdrawn from clinical use because of the associated
high rate of insufficiency. The mode of deterioration was
largely documented: valve design failure, tissue preparation
failure, or both was the main cause rather than pericardium
failure.3,4,12-14 Prosthetic ISPX valve failure in long-term
implantation has been well described by Schoen and
coworkers.2 They have reported that the characteristics of
SVD, NSVD, or both of ISPXs were intrinsic cuspal calci-
fication and design-related leaflet tears or commissural per-
forations. Leaflet tears of ISPXs were usually caused by
abrasions or fatigue of the tissue at the stent posts. Calcium
deposition on bioprosthesis was dependent on patient fac-
tors, such as age, renal function, and calcium intake.15 It
was hypothesized that calcification of bioprosthetic tissue
was due to inability of the devitalized cells to maintain a low
intracellular content of free calcium in the presence of high
extracellular calcium16; this was compatible with our
results. On the contrary, when compared with ISPXs, severe
cuspal tears and perforation were not seen and the degree of
calcification was milder in CEPXs. This might be attribut-
able to the improvement of heteropericardium fixation and
the design of the cuspal structure of CEPX valves.
We reported previously that tissue overgrowth, so-called
pannus formation, on the cusps of CEPX in the tricuspid
position made the cusps shrink and caused regurgitation.17
This tissue overgrowth might have been related to the
anatomic and hemodynamic characteristics of the right ven-
tricle. Because the right ventricle has a wedge-shaped con-
figuration, prosthetic cusps adjacent to the sewing cuff
might easily touch the remnant of the native valve and its
subvalvular component, resulting in thrombus formation
and tissue overgrowth. In this study the average patient age
and the duration of valve implantation were similar between
the CEPX and ISPX groups. The severity of tissue over-
growth from the sewing ring and struts was significantly
higher for CEPXs than for ISPXs. Severe tissue overgrowth
may have caused miscoaptation of the cusp closure line and
increased its rigidity, resulting in mitral regurgitation or
stenosis regurgitation, which are defined as nonstructural
dysfunctions.9 Thrombi formed on the fibrous tissue were
also recognized. A few months after the operation, fibrin
thrombi appeared on the sewing ring and cuspal leaflet.
Organization of the fibrin thrombi results in proliferation of
fibrous tissue. Thereafter, endothelialization should be con-
tinued. On the other hand, tissue overgrowth, accompanied
by endothelialization, is often observed in the sewing cuff of
any bioprosthesis and mechanical valves. CEPXs, which
have improved characteristics, also have another feature in
their design. The continuity of CEPX between sewing ring
and cuspal leaflet was notably smooth compared with that
of ISPXs. Therefore we speculate that the fibrous tissue
with endothelialization around the prosthetic valve might
have grown over a subtle gap between the sewing ring and
cuspal leaflets onto the prosthetic cusps adjacent to this
sewing ring, resulting in fibrous thrombus formation and tis-
sue overgrowth. We think that tissue overgrowth onto the
cuspal leaflet might be peculiar to CEPXs, and the shape of
CEPXs will probably be related to tissue overgrowth. In
addition, the styles of the sewing rings are markedly differ-
ent among CEPXs and ISPXs. The ISPX valve used Dacron
velour, whereas the CEPX valve used Teflon nonvelour.
This difference might be the main reason that there were
differences in tissue overgrowth and valve failure.
Other pathologic findings, cholesterol deposition, and
degeneration of collagen bundles of the xenograft should be
chronologic changes; the extent of these changes was not
significantly different between CEPXs and ISPXs.
The influence of patient age on the incidence of primary
tissue failure is well known.18 Neville and colleagues19
reported that 12-year actuarial freedom from structural dete-
rioration was 52% in patients under 60 years of age and
100% in patients over 60 years of age. Our data demon-
strated that the rate of freedom from reoperation caused by
SVD, NSVD, or both was worse at 12 years after the oper-
ation. According to the current strategy for mitral valve
replacement with a bioprosthesis, the majority of the candi-
dates were patients older than 60 years. This study, includ-
ing relatively younger patients, might underestimate the
durability of the CEPX. Use of the CEPX for elderly
patients will produce better durability, as reported previous-
ly by Neville and colleagues.19 At present, we mainly use
bioprostheses for elderly patients.
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TABLE 4. Multivariate analysis by stepwise discriminant
analysis
Wilks lambda F value P value
Leaflet tear 0.545 18.171 .005
Calcification 0.446 14.505 .035
Tissue overgrowth on atrial aspect 0.446 16.163 .013
Tissue overgrowth on ventricular aspect 0.757 18.792 .0001
TABLE 3. Microscopic comparison of explanted CEPX ver-
sus ISPX
Carpentier-Edwards Ionescu-Shiley 
valve (n = 20) valve (n = 23) P value
Tissue overgrowth area/ 15.3 ± 12.3 3.4 ± 6.5 .0001
whole cusp area (%)
Calcification area/whole 13.6 ± 11.6 31.5 ± 10.6 .0001
cusp area (%)
Maximum cuspal thickness 1029.4 ± 4.2 1509.1 ± 193.1 .0001
(µm)
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The absence of severe leaflet tears in CEPXs was a sig-
nificant advantage because acute regurgitation of the valve
causing acute cardiac failure has been avoided. The CEPX
structure, which followed the concept of near-anatomic con-
figuration of central flow trileaflet prostheses, still has
another structural limitation (ie, tissue overgrowth other
than chronologic degeneration of the cusp). We believe that
more modification of valve structure would be required for
better durability.
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